The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Hookipa Pharma
Stock and Other Ownership Interests - Hookipa Pharma
Recommended phase 2 dose (RP2D) of HB-200 arenavirus-based cancer immunotherapies in patients with HPV16+ cancers.
 
Siqing Fu
Research Funding - Abbisko (Inst); BeiGene (Inst); BioAtla (Inst); Boehringer Ingelheim (Inst); Exelis (Inst); Exelis (Inst); Greenfire Bio (Inst); Hookipa Pharma (Inst); IMV (Inst); Innovent Biologics (Inst); K-Group Beta (Inst); Lilly (Inst); Lyvgen Biopharma (Inst); MacroGenics (Inst); Millennium (Inst); NCCN (Inst); Nerviano Medical Sciences (Inst); NeuPharma, Inc. (Inst); NextCure (Inst); NIH/NCI (Inst); Ningbo NewBay Medical Technology (Inst); Novartis (Inst); NovoCure (Inst); Parexel International, LLC (Inst); PureTech (Inst); Sellas Life Sciences (Inst); Soricimed (Inst); SQZ Biotech (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Taiho Oncology (Inst); Treadwell Therapeutics (Inst); Turnstone Bio (Inst); Tyligand Bioscience (Inst); Vaccibody (Inst)
 
Lisle Nabell
No Relationships to Disclose
 
Alexander T. Pearson
Stock and Other Ownership Interests - Inovalon (I)
Consulting or Advisory Role - Abbvie; Ayala Pharmaceuticals; Elevar Therapeutics; Prelude Therapeutics
Research Funding - Abbvie (Inst); Kura Oncology (Inst)
 
Rom Leidner
Research Funding - Bristol-Myers Squibb (Inst)
Other Relationship - Celldex (Inst); Clinigen Group (Inst); OncoSec (Inst)
 
Douglas Adkins
Consulting or Advisory Role - Blueprint Medicines; Boehringer Ingelheim; Boehringer Ingelheim; Coherus Biosciences; CUE Biopharma; Eisai Europe; Exelixis; Immunitas; Kura Oncology; Merck; TargImmune Therapeutics; twoXAR; Vaccinex; Xilio Therapeutics
Research Funding - Aduro Biotech (Inst); AstraZeneca (Inst); BeiGene (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Cofactor Genomics (Inst); CUE Biopharma (Inst); Debiopharm Group (Inst); Epizyme (Inst); Exelixis (Inst); Gilead Sciences (Inst); Hookipa Biotech (Inst); Immutep (Inst); Innate Pharma (Inst); ISA Pharmaceuticals (Inst); Kura Oncology (Inst); Lilly (Inst); Matrix Biomed (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Rubius Therapeutics (Inst); Sensei Biotherapeutics (Inst); Shanghai Denovo (Inst); Vaccinex (Inst)
 
Marshall R. Posner
Consulting or Advisory Role - Cel-Sci; Merck
Research Funding - AstraZeneca (Inst); Hookipa Pharma (Inst); Innate Pharma (Inst); ISA Pharmaceuticals (Inst); Regeneron (Inst)
Patents, Royalties, Other Intellectual Property - anti-Staphylococcal Monoclonal antibody (Inst); Uptodate editor
(OPTIONAL) Uncompensated Relationships - My Personal Therapeutics
 
Jorge J. Nieva
Stock and Other Ownership Interests - Cansera; Epic Sciences; Indee P/L; Quantgene
Consulting or Advisory Role - AstraZeneca; Naveris
Research Funding - Genentech (Inst); Merck (Inst)
Patents, Royalties, Other Intellectual Property - Patent Pending - movement and unexpected healthcare encounters
 
Debra L. Richardson
Consulting or Advisory Role - AstraZeneca; Genentech/Roche; GlaxoSmithKline; Mersana
Research Funding - Aravive (Inst); ArQule (Inst); AstraZeneca (Inst); Deciphera (Inst); Five Prime Therapeutics (Inst); Fujifilm (Inst); Genentech (Inst); Harpoon therapeutics (Inst); Hookipa Biotech (Inst); Innovent Biologics (Inst); Karyopharm Therapeutics (Inst); Lycera (Inst); Merck (Inst); Mersana (Inst); Roche (Inst); Syros Pharmaceuticals (Inst); Tesaro (Inst)
 
Agustin Pimentel
Stock and Other Ownership Interests - biontech; Pfizer
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Foundation Medicine; QED Therapeutics; Taiho Pharmaceutical
Research Funding - Array BioPharma (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Halozyme (Inst); Hookipa Biotech (Inst); Hoosier Cancer Research Network (Inst); Isofol Medical (Inst); Ludwig Institute for Cancer Research (Inst); Turnstone Bio (Inst); Turnstone Bio (Inst)
 
Sanjay Goel
Stock and Other Ownership Interests - Johnson and Johnson; Merck; Moderna Therapeutics
Honoraria - Amgen; Merck
Research Funding - BeiGene (Inst); Deciphera (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); PharmaMar (Inst); Takeda (Inst); TLC PharmaChem (Inst)
Patents, Royalties, Other Intellectual Property - I have a patent with a co-inventor, John Mariadason, Ph.D, entitled "Method Of Determining The Sensitivity Of Cancer Cells To EGFR Inhibitors Including Cetuximab, Panitumumab And Erlotinib.", Patent No. 20090258364
 
Stuart J. Wong
Research Funding - Merck; Novartis
 
Alan Loh Ho
Consulting or Advisory Role - AffyImmune Therapeutics; AstraZeneca; Ayala Pharmaceuticals; Bristol-Myers Squibb; Cellestia Biotech; CureVac; CureVac; Eisai; Eisai; Exelixis; Genzyme; InxMed; Kura Oncology; McGivney Global Advisors; Merck; Novartis; Prelude Therapeutics; Regeneron; Rgenta; Sanofi; Sun Pharma; TRM Oncology
Speakers' Bureau - Medscape; Novartis; Omniprex America
Research Funding - Allos Therapeutics; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Ayala Pharmaceuticals; Ayala Pharmaceuticals; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Elevar Therapeutics; Genentech/Roche; Kolltan Pharmaceuticals; Kura Oncology; Lilly; Merck; Novartis; Novartis; Novartis; Novartis; Pfizer
Travel, Accommodations, Expenses - Ayala Pharmaceuticals; Ignyta; Janssen Oncology; Klus Pharma; Kura Oncology; Kura Oncology; Kura Oncology; Merck
 
Ari Rosenberg
Stock and Other Ownership Interests - Galectin Therapeutics
Consulting or Advisory Role - EMD Serono; Nanobiotix
Research Funding - Sysmex
 
Matthew H. Taylor
Honoraria - Bayer; Bristol Myers Squibb Foundation; Eisai; Merck; Pfizer; Regeneron; Roche
Consulting or Advisory Role - Array BioPharma; Bayer; Blueprint Medicines; Bristol-Myers Squibb; Eisai; Loxo; Novartis; Sanofi
Speakers' Bureau - Blueprint Medicines; Bristol-Myers Squibb; Eisai; Merck
Research Funding - Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Loxo/Bayer (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst); Seagen (Inst)
 
Raghad Abdul-Karim
No Relationships to Disclose
 
Corinne Iacobucci
Employment - Hookipa Pharma
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Xiaoping Qing
No Relationships to Disclose
 
Kia Katchar
Employment - Hookipa Pharma
Stock and Other Ownership Interests - Hookipa Pharma
 
Katia Schlienger
Employment - Hookipa Pharma; Merck
Stock and Other Ownership Interests - Hookipa Pharma; Merck
Patents, Royalties, Other Intellectual Property - Hookipa Pharma
Travel, Accommodations, Expenses - Hookipa Pharma; Merck
 
David G. Pfister
Consulting or Advisory Role - Boehringer Ingelheim; Incyte
Research Funding - AstraZeneca (Inst); Atara Biotherapeutics (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Hookipa Pharma (Inst); Lilly (Inst); MedImmune (Inst); MeiraGTx (Inst); Merck (Inst); Novartis (Inst); Regeneron (Inst)